Case Report

A rare case of non-Hodgkins lymphoma of testis: case study and review of literature

Sreeramulu P. N.*, Karthik Hareen T. V. K., Rakesh N., Prajith Reddy V.

Department of Surgery, SDU Medical College, Kolar, Karnataka, India

Received: 19 December 2016
Accepted: 20 January 2017

*Correspondence:
Dr. Sreeramulu P. N.,
E-mail: Karthikhareen08@gmail.com

ABSTRACT

Primary testicular lymphoma is a rare non-Hodgkin’s lymphoma, usually seen in people around 50 years. It accounts for 1% of all non-Hodgkin’s lymphoma. It usually involves bilateral testes. Orchidectomy followed by chemotherapy is the treatment modality. Central nervous system is the common site for extra nodal site followed by skin, lung, and pleura. A 70 years old male patient presented with complaint of painless swelling of the left testes since 1 year. On examination left testes enlarged in size measuring around 8x5x4 cm. Ultrasound showed features suggestive of malignancy? Seminoma left testes. Orchidectomy was done and sent for histopathological examination. Histopathological report showed features of non-hodgkin’s lymphoma. Patient was started with systemic chemotherapy. 3 cycles of CHOP regimen was given to the patient at 21 days interval. Primary testicular tumour being a rare condition, early diagnosis and treatment with orchidectomy followed by chemotherapy is the first choice. Prognosis is poor. Secondary spread to CNS advocates the use of intrathecal chemotherapy.

Keywords: Central nervous system, CHOP regimen, Genital neoplasms, Injections, Lymphoma, Orchidectomy, Testis

INTRODUCTION

Testicular lymphoma is a rare disease accounting for 1-7% of all testicular tumour. Patients present with painless enlarged testes. Bilateral involvement is the unique feature of this tumour. It usually spreads to extra nodal sites, CNS being the most common site. B cell type is the most common histological type seen. Orchidectomy followed by chemotherapy is the standard treatment strategy. CNS prophylaxis with intrathecal chemotherapy for secondaries is advised. Relapse is common even after complete remission of the disease. In this report, we discuss about the clinical presentation, diagnosis and treatment of primary testicular tumour.

CASE REPORT

A 70 years old male patient presented with chief complaints of swelling of left testes since 1 year. Swelling was painless in nature. On examination patient was moderately built and nourished and all parameters were within normal range.

Local examination revealed enlargement of left testes; it measured around 8x5x5 cm. There was no local rise of temperature or tenderness.

Epididymis was normal. Ultrasonography suggested features of malignancy? Seminoma left testes. High orhidectomy of left testes was done and sent for histopathological examination.

Histopathological examination revealed features of Non-Hodgkins lymphoma. CT Brain and CECT Abdomen were done. CT Brain showed normal study and CECT Abdomen showed few subcentimetric paraaortic lymph nodes. The patient was diagnosed to have Stage 2 non-Hodgkins lymphoma. Patient was started with systemic
CHOP Regimen chemotherapy. 3 cycles of chemotherapy at 21 days interval was given.

DISCUSSION

Epidemiology and incidence

Primary TNHL was first described as a clinically entity in 1866. It is a rare disease and accounts for 1% of all non-Hodgkin’s lymphoma (NHL) cases, 2% of all extranodal lymphomas and 5% of all testicular neoplasms. However, secondary testicular involvement is not uncommon in advanced NHL cases, either as part of the terminal disease or in autopsy findings, and up to 20% of patients dying due to disseminated NHL have been reported to have microscopic testicular invasion.

Affected age group and bilaterality

TNHL usually occurs in older men and is the most common testicular malignancy in men between sixty and eighty years of age. High incidence of bilateral testicular involvement, which is a unique feature of TNHL, was first reported by Abeshouse et al. TNHL is now considered to be the most common bilateral tumor of the testes, with reported incidence of bilateral metachronous testicular involvement of 35% and bilateral synchronous testicular involvement of 3%. Other authors have reported the incidence of bilateral involvement of about 10-40%.

Etiological factors and dissemination patterns

There are neither any well-documented etiological nor predisposing factors nor any significant associations existing between histories of trauma, chronic orchitis or cryptorchidism and subsequent development of TNHL. TNHL has a predilection for dissemination to non-contiguous extranodal sites such as the CNS, Waldeyer’s ring, skin and lungs. Martenson et al. reported a 10% incidence of CNS involvement in the initial failure and 20% in subsequent relapses. CNS relapses have been reported in 14% of stage I cases and 10.5% of stage II cases. In a series of 22 patients, the CNS or the contralateral testis were involved in all the patients who failed to respond to primary therapy and in 50% of those who relapsed from complete remission.

Histological classification

According to the working formulation of the United States National Cancer Institute, approximately 68% of TNHL cases are classified as intermediate grade, diffuse large B-cell subtype, followed by high-grade, diffuse small non-cleaved subtype in about 30% of the patients. There is no prognostic advantage for any pathological subtype. Immunohistochemistry (IHC) studies confirm the majority of TNHL cases to be of B-cell origin, with lesser occurrence of T-cell lymphoma. Histopathological differentiation of TNHL from seminoma is usually a challenge. Other conditions that might resemble TNHL are embryonal cell carcinoma, granulomatous orchitis, pseudolymphoma, plasmacytoma and rhabdomyosarcoma. Serum lactate dehydrogenase (LDH) levels have been correlated with tumor aggressiveness, whereas other tumor markers such as serum beta human chorionic gonadotropin (HCG) and serum alpha-fetoprotein (AFP) are rarely elevated in TNHL cases. Abbadi et al studied 18 patients and classified their disease as primary testicular lymphoma with germinal center B-cell-like and non-germinal center B-cell-like by means of the IHC expression of CD10, Bcl-6 and MUM1. They found that 89% of the primary testicular lymphoma of the diffuse large B-cell type belonged to the non-germinal center Bcell- like subgroup and all exhibited high proliferative activity. The germinal center B-cell-like type of primary testicular lymphoma was uncommon and was seen mostly in HIV-positive patients.

Treatment

Early stage

Although there is enough data on TNHL and its management, there are very few population-based studies, and thus the treatment has not been standardized. For stages IE and IIE, there is universal agreement on orchidectomy as the initial treatment. If treated with orchidectomy alone, the majority of these patients relapse within the first two years at various extranodal sites, and hence the use of adjuvant systemic chemotherapy, radiotherapy and also prophylactic intrathecal chemotherapy has been emphasized. In a series of 16 patients, the median survival exceeded 57 months for those with stage IE disease, whereas it was six months for patients with advanced disease. No patient with disease that had spread to or beyond the para-aortic lymph nodes survived beyond 19 months. According to the same study, for stage IIE, radical irradiation offered the potential for cure, for all the pathological subtypes. In a similar study, Connors et al. reported that the four-year actuarial survival was 93% in a group of 15 patients with stage IE and IIE disease who were treated with orchidectomy and doxorubicin-based chemotherapy, with prophylactic radiotherapy for the uninvolved contralateral testis. In contrast to the data from Connors et al. and Tepperman et al., another report on 24 patients showed that 10 out of 12 patients who underwent orchidectomy alone died of disseminated disease, and 50% died within the first six months following orchidectomy. The patients with stage IE and IIE disease who were treated with orchidectomy and irradiation of regional lymph nodes also presented an association with relapse. Stage IE is unique in that it is potentially curable in small subpopulations by means of orchidectomy alone. On the
other hand, in other groups, late relapse and distant spreading that was non-responsive to retreatment with irradiation or chemotherapy has been evident.

However, routine chemotherapy may not be recommendable in stage IE disease. According to a study on 34 patients registered with the British National Lymphoma Investigation (BNLI), adjuvant chemotherapy using the cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) protocol was insufficient to prevent CNS relapse. In a Danish population-based NHL registry report, 24 out of 39 patients had localized disease. Early-stage patients who were treated with orchidectomy and doxorubicin-based chemotherapy had a relapse rate of 15.4%, while for those not given adjuvant chemotherapy, the relapse rate was 63.6%. The median relapse-free survival was 28 and 14 months and the overall two and five-year survival rates were 43% and 17%, respectively, for these two groups of patients. The overall complete remission rate for stages IE and IIE was 96%, in contrast to 7% for stage IV disease. Failure-free survival of 16% at 153 months was reported for a group of 22 patients at the MD Anderson Cancer Center. Either the CNS or the contralateral testis was involved in all the patients who failed to respond to primary therapy and in 50% of those who relapsed from complete remission. In that study, relapsed patients had received neither prophylactic intrathecal chemotherapy nor irradiation for the contralateral testis. In a similar review of 29 patients, all 16 with limited disease received doxorubicin-based chemotherapy following orchidectomy. Prophylactic radiotherapy for regional lymph nodes was given to 85% of the patients with limited disease. After a median follow-up of seven years, only one-third of patients with early-stage and slightly more than 10% of patients with advanced disease were alive.

In a large series of 84 patients, 50% had stage IE disease. The treatment groups were divided into surgery only, surgery-radiotherapy, surgery-chemotherapy and surgery-radiotherapy-chemotherapy. None of the patients received CNS prophylaxis. At the end of the initial treatment, 61 (72.6%) achieved complete remission. Out of these, 32 patients relapsed and the most frequent site of recurrence was the CNS. Also, 50% of the stage IE patients relapsed. According to that study, there was no significant improvement in overall survival, disease-specific survival (DSS) or disease-free survival (DFS) in cases of stage IE disease when treated with orchidectomy alone or when combined with chemotherapy or radiation. The median overall survival and DFS in that study were 32 months and 36 months respectively. Thus, treatment of early stage TNHL is controversial. Irradiation therapy alone is also not considered effective in view of the high rate of dissemination. Similarly, treatment with adjuvant doxorubicin has a high relapse rate despite achieving complete remission for the majority of patients.

Advanced stage disease

For stage IIE and IVE disease, the treatment of choice is systemic chemotherapy, with irradiation reserved for symptomatic and bulky localized deposits. Although the majority of patients achieve complete remission, most of them relapse, with a median survival of three to five months. In view of the high risk of CNS relapse, even in patients who achieve complete remission with primary therapy, CNS prophylaxis should be considered in all advanced-stage patients. Similarly, prophylactic irradiation for the contralateral testis is recommended, since the relapse rate in the contralateral testis is up to 50%. Nevertheless, contrary to this approach, some authors argue against prophylactic radiotherapy for the contralateral testis.

CONCLUSION

Thus, to summarize, TNHL is a rare tumor of the testes, with an incidence of only 1 to 7%. Nonetheless, it is the most common testicular tumor in older males. TNHL is unique in its propensity for bilateral involvement and is the most common bilateral testicular tumor. The prognosis is generally poor, since disseminated disease is usually evident within the first two years following the diagnosis. Advanced-stage disease is usually managed with doxorubicin-based chemotherapy. For early-stage disease, opinion is divided regarding systemic chemotherapy following orchidectomy. The high incidence of spreading, especially to the CNS, leads to advocacy of the use of CNS prophylaxis with intrathecal chemotherapy. Prospective multicenter trials incorporating a large number of patients would lead to better treatment options for this subtype.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES


